Cipla receives EIR for API manufacturing facility in Bommasandra, Bangalore
(09 May 2020)
Cipla announced that following the inspection by the United States Food and Drug Administration (USFDA) at its API manufacturing facility in Bommasandra, Bangalore from 20 January 2020 to 24 January 2020, the Company has received the Establishment Inspection Report (EIR), indicating closure of the inspection.